News
Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...
19h
MedPage Today on MSNOnce-Monthly Oral PrEP Option Appears Safe, Tolerable in Adults at Low Risk of HIVThe investigational oral pre-exposure prophylaxis (PrEP) agent MK-8527 showed a similar, well-tolerated safety profile to ...
The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...
4don MSN
The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
1d
AllAfrica on MSNUganda: Rise in HIV/Aids Cases Feared After U.S. Aid CutsScientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th ...
For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...
Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...
Let us refresh the old gold Buddhist tale of The Quail and the Net: ldquo;Long ago a flock of quails lived in a forest .
11h
The Star on MSNResearchers uncover new treatment modes for older people with HIVExperts have proposed new treatment modes for older people with HIV. The new treatment does not cause the health-threatening ...
WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.
Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...
The House passed legislation on Thursday clawing back $9 billion in federal funding for global aid projects, which would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results